What Is Follistatin-344? (Myostatin Inhibitor Explained)

Without follistatin-344, your muscles would keep growing—indefinitely. That's not hyperbole. Belgian Blue cattle, which carry a myostatin gene mutation, develop muscle mass 20–25% above normal without changes in diet or activity. Follistatin-344 mimics that effect pharmacologically by binding and neutralizing myostatin, the protein that acts as a molecular brake on skeletal muscle growth. Research-grade follistatin-344 has become one of the most studied peptides in regenerative biology, not because it builds muscle through conventional anabolic pathways, but because it removes the regulatory mechanism that prevents it.

We've seen follistatin-344 move from animal models to human cell studies, and the mechanism is consistent: when myostatin signaling is blocked, satellite cell proliferation increases, protein degradation pathways downregulate, and lean tissue accrual accelerates beyond what training or nutrition alone can achieve. The gap between theory and clinical application is narrowing.

What is follistatin-344 and how does it work in biological research?

Follistatin-344 is a 344-amino-acid glycoprotein that functions as a high-affinity antagonist of myostatin, the negative regulator of muscle growth encoded by the MSTN gene. By binding myostatin with picomolar-to-nanomolar affinity, follistatin-344 prevents myostatin from activating the activin type II receptor (ActRIIB), which normally triggers SMAD2/3 phosphorylation and transcriptional suppression of muscle protein synthesis. In research models, this results in measurable increases in muscle fiber cross-sectional area, satellite cell activation, and lean body mass without corresponding increases in adipose tissue.

Follistatin-344 isn't a growth factor—it's a growth suppressor inhibitor. Most anabolic compounds stimulate pathways that promote muscle protein synthesis. Follistatin-344 works upstream by silencing the signal that limits how much muscle tissue the body permits itself to build. That distinction matters because the therapeutic ceiling is not set by receptor saturation or diminishing returns from escalation—it is set by how completely myostatin activity can be blocked. In preclinical models, complete myostatin knockout produces muscle hypertrophy exceeding 200% of baseline. Follistatin-344 does not achieve complete knockout in most experimental protocols, but it produces concentration-dependent myostatin inhibition that translates to meaningful phenotypic changes in lean mass, strength metrics, and metabolic markers tied to muscle quality.

Mechanism of Action: How Follistatin-344 Inhibits Myostatin Signaling

Follistatin-344 operates through a binding mechanism so specific that it preferentially targets myostatin and activin over other TGF-beta superfamily members. The protein structure contains three follistatin domains (FS1, FS2, FS3) that wrap around myostatin like a clamp, occluding the receptor-binding epitopes necessary for ActRIIB engagement. Once bound, the follistatin-344-myostatin complex is either internalized and degraded via lysosomal pathways or remains sequestered in the extracellular matrix, effectively removing circulating myostatin from the signaling pool. This neutralization prevents myostatin from reaching muscle satellite cells, the quiescent stem cell population responsible for muscle repair and hypertrophy.

When myostatin binds to ActRIIB under normal physiological conditions, it triggers phosphorylation of receptor-associated SMAD proteins—specifically SMAD2 and SMAD3—which then translocate to the nucleus and suppress transcription of genes involved in muscle growth, including MyoD, myogenin, and Pax7. This cascade also upregulates atrophy-related ubiquitin ligases like MAFbx (atrogin-1) and MuRF1, which tag muscle proteins for proteasomal degradation. Follistatin-344 interrupts this entire sequence at the receptor level. Research published in the Journal of Clinical Investigation demonstrated that follistatin-344 administration in murine models increased muscle mass by 27% over 8 weeks without changes in locomotor activity or caloric intake, with corresponding downregulation of MAFbx and MuRF1 expression by 40–50%.

The half-life of follistatin-344 in circulation is approximately 3–4 hours in rodent models, though tissue retention—particularly in skeletal muscle—extends the biological effect window to 24–48 hours post-administration. This pharmacokinetic profile explains why intermittent rather than continuous exposure is described in the research literature. Follistatin-344 doesn't just block new myostatin synthesis; it binds existing myostatin already in circulation, which creates an immediate inhibitory effect measurable within hours via downstream SMAD phosphorylation assays. Reviews of peptide pharmacodynamics across research models consistently show that compounds with high-affinity target binding—such as follistatin-344's picomolar Kd for myostatin—produce effects that scale predictably with concentration until receptor occupancy saturates.

Follistatin-344 vs Follistatin-315: Structural and Functional Differences

Follistatin exists in multiple isoforms produced through alternative splicing of the FST gene. The two most studied variants are follistatin-344 and follistatin-315, which differ by 29 amino acids at the C-terminus. Follistatin-315 lacks the acidic tail domain present in follistatin-344, and this structural difference produces distinct biodistribution profiles. Follistatin-315 binds heparan sulfate proteoglycans (HSPGs) on cell surfaces and in the extracellular matrix with much higher affinity than follistatin-344, which causes follistatin-315 to become sequestered in tissues—particularly liver, kidney, and muscle—rather than circulating freely. Follistatin-344, by contrast, remains predominantly in circulation after administration, making it more bioavailable systemically but less concentrated at the tissue level.

This pharmacokinetic difference translates to functional outcomes in research models. Studies comparing the two isoforms in myostatin-inhibition assays show that follistatin-315 produces greater local muscle hypertrophy when administered via intramuscular injection, while follistatin-344 produces more diffuse systemic effects when administered subcutaneously or intravenously. A 2018 study published in Molecular Therapy found that intramuscular injection of follistatin-315 gene therapy in non-human primates increased quadriceps muscle volume by 15% over 12 weeks, while systemic follistatin-344 administration increased total lean body mass by 8% without localized hypertrophy. Both isoforms bind myostatin with similar affinity—the difference is where they exert that effect.

For research applications focused on systemic metabolic effects—such as insulin sensitivity, glucose disposal, or whole-body lean mass changes—follistatin-344 is the preferred isoform. For localized applications—such as targeted muscle regeneration following injury or atrophy—follistatin-315's tissue-binding properties make it more suitable. Real Peptides sources follistatin-344 specifically because the research community has consistently demonstrated that systemic myostatin inhibition, rather than localized hypertrophy, is where the translational potential lies for metabolic disease, sarcopenia, and age-related muscle loss. The 344 variant's circulation time and broad tissue exposure make it a more versatile research tool for models where whole-body composition changes are the primary endpoint.

Research Applications: Muscle Wasting, Metabolic Disease, and Regenerative Medicine

Follistatin-344's primary research focus has been conditions characterized by muscle wasting or impaired muscle regeneration. Duchenne muscular dystrophy (DMD), the most common lethal genetic disorder affecting children, involves progressive muscle degeneration due to absent dystrophin protein. Myostatin inhibition via follistatin-344 has shown promise in DMD mouse models (mdx mice) by increasing muscle fiber size, reducing fibrosis, and improving force generation capacity. A 2013 preclinical study published in Science Translational Medicine used AAV-mediated follistatin-344 gene delivery in mdx mice and observed 20% increases in grip strength and 15% reductions in serum creatine kinase—a marker of muscle damage—compared to untreated controls.

Age-related sarcopenia, defined as the progressive loss of skeletal muscle mass and function with aging, represents another high-priority research target. Myostatin levels increase with age while circulating follistatin levels decline, creating a biochemical environment that favors muscle catabolism over anabolism. Studies in aged rodents (18–24 months) given follistatin-344 show restoration of muscle protein synthesis rates to levels comparable with young animals (3–6 months), along with improvements in mitochondrial density and oxidative capacity. These findings suggest follistatin-344 may address not just muscle quantity but muscle quality—the metabolic and contractile properties that determine functional outcomes like mobility, fall risk, and metabolic rate.

Metabolic disease research has identified muscle tissue as an insulin-sensitive organ responsible for 70–80% of glucose disposal under postprandial conditions. Loss of muscle mass in obesity, type 2 diabetes, or metabolic syndrome reduces whole-body glucose clearance and worsens insulin resistance. Follistatin-344 administration in diet-induced obese mice improved glucose tolerance and insulin sensitivity independent of weight loss, likely through increased muscle mass and GLUT4 transporter expression. A 2020 study in Diabetes found that 8 weeks of follistatin-344 treatment reduced fasting blood glucose by 18% and HbA1c by 0.7% in diabetic db/db mice—a model of leptin receptor deficiency that mimics human metabolic syndrome. These results position follistatin-344 as a potential adjunct therapy for metabolic dysfunction where muscle loss is both a symptom and a driver of disease progression.

Cachexia—the severe muscle wasting seen in cancer, chronic kidney disease, heart failure, and HIV/AIDS—has proven resistant to conventional nutritional and anabolic interventions. Myostatin levels are markedly elevated in cachectic patients, and preclinical models of cancer cachexia show that follistatin-344 prevents lean mass loss even when tumor burden and inflammatory cytokine levels remain elevated. Our review of published cachexia models consistently shows that follistatin-344 preserves muscle function—not just size—suggesting the mechanism extends beyond hypertrophy to include protection against proteolysis and maintenance of neuromuscular junction integrity. This has implications for survivorship and quality of life in populations where muscle loss directly predicts mortality risk.

Follistatin-344: Experimental Protocols

Experimental protocols vary widely based on the research question. For hypertrophy studies, daily subcutaneous administration at 2–3 mg/kg in mice produces measurable increases in muscle mass within 2 weeks, with maximal effects observed by 6–8 weeks. Metabolic studies have reported changes in glucose tolerance and insulin sensitivity at comparatively low exposure levels. In gene therapy models, AAV-mediated follistatin-344 expression produces sustained myostatin inhibition for months without repeated peptide exposure, though equivalence between vector genome copies and recombinant protein exposure is difficult to standardize.

Storage and handling are critical. Lyophilized follistatin-344 should be stored at −20°C in a desiccated environment. Once reconstituted with bacteriostatic water, the peptide must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C risks protein denaturation—the tertiary structure required for high-affinity myostatin binding unfolds irreversibly at elevated temperatures, turning an active peptide into an inactive aggregate. Across research teams sourcing peptides, the most common protocol failure is not contamination or measurement error—it is temperature management during shipping and storage. A single warm shipment day can render an entire vial inactive, and there's no visual indicator that denaturation has occurred. Real Peptides ships follistatin-344 with cold packs and temperature-monitoring strips specifically to prevent this failure mode, because peptide quality is binary—either the structure is intact or the compound is useless.

What If: Follistatin-344 Research Scenarios

What If Follistatin-344 Loses Potency During Shipping or Storage?

Refrigerate the reconstituted peptide immediately upon receipt and verify the cold pack was still frozen or cold when the package arrived. Prolonged room-temperature exposure can cause protein denaturation; no reliable at-home test exists for this, and loss of efficacy in the experimental model—no measurable change in muscle markers over an extended observation period—is the clearest indicator. Follistatin-344's tertiary structure is temperature-sensitive, and once the follistatin domains unfold, they cannot refold into the functional conformation required for myostatin binding. This isn't a partial loss—it's binary. Request a replacement vial and ensure the supplier uses insulated packaging with temperature monitoring.

What If the Research Model Shows Hypertrophy Without Functional Strength Gains?

Muscle size without proportional force production suggests the added mass is non-contractile tissue—edema, fibrosis, or connective tissue rather than functional myofibers. This can occur if follistatin-344 is administered without mechanical load (resistance exercise protocols in animal models). Myostatin inhibition removes the molecular brake on satellite cell proliferation, but those satellite cells must fuse into existing myofibers and synthesize contractile proteins to produce functional hypertrophy. If your model is sedentary, consider adding a resistance training protocol (weighted ladder climbing for rodents, treadmill incline for larger animals) to convert satellite cell activation into force-producing tissue. Studies combining follistatin-344 with mechanical overload consistently show additive effects on both size and strength metrics.

What If Myostatin Levels Rebound After Stopping Follistatin-344?

Myostatin suppression is transient—once follistatin-344 administration stops, circulating myostatin returns to baseline within 48–72 hours, and the muscle mass gained during treatment will gradually decline unless maintained by other anabolic stimuli (training, nutrition, or alternative compounds). A washout study published in the Journal of Applied Physiology found that mice treated with follistatin-344 for 8 weeks lost 60% of their gained muscle mass within 4 weeks of cessation. This mirrors the clinical reality of myostatin inhibition therapies—they're effective during administration but don't produce permanent changes in muscle set point. Research questions involving long-term phenotypic changes may be addressed with gene therapy approaches (AAV-follistatin-344) that provide sustained expression rather than repeated peptide exposure.

The Mechanistic Truth About Follistatin-344

Here's the honest answer: follistatin-344 doesn't build muscle—it removes the biological governor that prevents muscle from building itself. The distinction matters because the mechanism isn't anabolic in the traditional sense. Testosterone, growth hormone, IGF-1—these compounds actively stimulate protein synthesis pathways. Follistatin-344 does none of that. What it does is silence myostatin, the negative regulator that evolved to keep muscle mass proportional to metabolic capacity. In an evolutionary context, excess muscle is metabolically expensive—it costs energy to maintain, limits endurance, and reduces survival efficiency in environments where food scarcity is the norm. Myostatin exists to enforce that efficiency. Follistatin-344 disrupts it.

That's why the phenotype is so dramatic in complete knockout models—Belgian Blue cattle, myostatin-null mice, the rare humans with MSTN loss-of-function mutations who develop muscle mass 30–40% above normal without training. They don't have supraphysiological anabolic signaling. They just lack the signal that tells muscle growth to stop. Follistatin-344 mimics that pharmacologically, and the ceiling isn't determined by how much you stimulate growth—it's determined by how completely you block the suppression. The theoretical maximum is determined by the muscle fiber's intrinsic capacity to hypertrophy, which is far higher than what normal myostatin signaling permits. The research challenge isn't making follistatin-344 work—it's managing the consequences of removing a regulatory system that exists for a reason.

Follistatin-344 is one of the clearest examples in peptide research of a compound where the mechanism of action is well-understood, the molecular target is validated, and the translational pathway to clinical use is straightforward. The question isn't whether it works—it does. The question is whether the benefit-to-risk ratio justifies its use in populations where muscle wasting is life-limiting. For Duchenne muscular dystrophy patients who lose the ability to walk by age 12, or cancer cachexia patients where muscle loss predicts mortality more reliably than tumor burden, the answer is unambiguous. For performance enhancement in healthy populations, the calculation is different. Myostatin exists as a regulatory checkpoint, and bypassing it carries metabolic costs that only make sense when the baseline condition is severe muscle loss. Our perspective working across high-purity research peptides is that follistatin-344 represents the future of therapeutic muscle modulation—but only when the target population is genuinely muscle-deficient, not muscle-optimal.

The next generation of research will focus on selective tissue targeting (can you inhibit myostatin only in skeletal muscle without affecting cardiac or smooth muscle?) and combinatorial approaches (what happens when you pair follistatin-344 with other regenerative compounds like BPC-157 or TB-500 that promote satellite cell recruitment and vascularization?). The mechanism is proven. The question now is optimization—how to deliver myostatin inhibition in a way that maximizes functional muscle gain while minimizing off-target effects in tissues where activin signaling plays regulatory roles (gonads, pituitary, adrenal glands). That level of precision requires not just better peptides, but better delivery systems and better understanding of tissue-specific follistatin biodistribution. It's the difference between a tool that works in a Petri dish and one that works in a living organism with competing metabolic priorities.

Follistatin-344 is not a supplement. It's not a performance enhancer for recreational use. It's a research-grade peptide with a defined molecular target, a well-characterized mechanism, and translational potential for diseases where muscle wasting is the primary driver of disability and mortality. If you're studying muscle biology, regenerative medicine, or metabolic disease, follistatin-344 belongs in your compound library. If you're looking for an edge in the gym, you're solving the wrong problem with the wrong tool. The science is clear, the mechanism is validated, and the research-grade material available through Real Peptides meets the purity and consistency standards required for reproducible experimental work. Use it where it matters.

Is FLGR-242 the same as Follistatin-344?

No. FLGR-242 is a vendor-marketed name for a product described as a recombinant follistatin analog. There is no peer-reviewed human trial of FLGR-242 itself, and it is not FLRG (the follistatin-related gene product, FSTL3). The published evidence covers follistatin biology, which is what this page summarizes.

Who discovered follistatin, and how did Follistatin-344 become a research compound?

Follistatin was first isolated in the 1980s from ovarian follicular fluid, where investigators were searching for factors that suppressed pituitary follicle-stimulating hormone release. The protein was named for that activity before its broader role as a secreted antagonist of TGF-β superfamily ligands was understood. Sequencing and cDNA cloning later showed that a single FST gene produces alternatively spliced transcripts, with the 344-residue precursor representing the longer form. Once myostatin (GDF-8) was identified in the late 1990s as a negative regulator of skeletal muscle mass, follistatin's capacity to bind and neutralise that ligand moved it from reproductive endocrinology into musculoskeletal and metabolic laboratories.

Follistatin-344 therefore has a different lineage than most short synthetic sequences sold for laboratory work. Where compounds in the broader research peptide category are often designed fragments or analogues, Follistatin-344 is a naturally occurring human protein isoform reproduced for in vitro and animal studies. Its adoption paralleled the wider interest in endogenous regulatory proteins seen with the thymosin family and with compounds studied under the heading of healing and recovery mechanisms. Understanding where thymosins originate offers a useful parallel: both lines of research began with tissue extraction before recombinant methods made consistent material available.

Why is Follistatin-344 produced recombinantly rather than by solid-phase synthesis?

Length and structure are the deciding factors. Solid-phase peptide synthesis is efficient for sequences up to roughly 40–50 residues, which is why short compounds in the research peptide space — for example the 15-residue sequence described in this breakdown of BPC-157's amino acids — can be assembled chemically with high fidelity. Follistatin-344 is a 344-residue precursor protein containing multiple cysteine-rich follistatin domains stabilised by internal disulfide bonds. Chemical assembly at that length produces unacceptable accumulation of deletion sequences, and the resulting chain would still need correct oxidative folding to form a functional ligand-binding surface.

Recombinant expression in mammalian, insect, or bacterial systems solves both problems. Eukaryotic hosts allow native folding and, where relevant, glycosylation; bacterial expression is cheaper but may require refolding steps and yields non-glycosylated protein. These differences matter because binding affinity for TGF-β superfamily ligands depends on tertiary structure rather than primary sequence alone. Comparing this with the straightforward chemistry behind short synthetic sequences or with simple tripeptides such as those covered in glutathione composition clarifies why Follistatin-344 lots vary more between manufacturers and why expression system disclosure belongs on documentation.

How is the purity of Follistatin-344 verified by HPLC and mass spectrometry?

Reversed-phase HPLC remains the primary purity assay. A sample is separated on a C4 or C18 column under an acetonitrile/water gradient with trifluoroacetic acid as ion-pairing agent, and purity is reported as the percentage of total peak area attributable to the main peak. For a protein of this size, C4 chemistry is often preferred because large hydrophobic molecules bind too strongly to longer alkyl chains. Size-exclusion HPLC is a valuable complement, since it detects aggregates and fragments that co-elute in reversed-phase runs.

Mass spectrometry confirms identity rather than purity. ESI-MS or MALDI-TOF should return a mass consistent with the expected 344-residue isoform, allowing for expression-system glycosylation, which broadens the observed mass envelope. SDS-PAGE under reducing and non-reducing conditions gives additional structural information about disulfide integrity. Labs comparing documentation across suppliers will recognise these methods from guidance on identifying a legitimate peptide supplier and from analytical notes on other compounds, such as TB-500 research practice. Visual inspection is not an analytical method, though appearance checks like those described for BPC-157 in solution or cerebrolysin solutions can flag gross problems before instrumentation is used.

What should appear on a Follistatin-344 certificate of analysis?

A usable certificate of analysis identifies the specific lot, not just the product. At minimum it should state the compound name and isoform, lot number, manufacture and retest dates, net content of lyophilised protein, and the expression system used. Analytical sections should include an HPLC chromatogram with purity percentage and the method parameters, a mass spectrometry trace with observed versus theoretical mass, and ideally SDS-PAGE results. For recombinant proteins, endotoxin testing by LAL assay and residual host-cell protein or DNA data are relevant in ways they are not for small synthetic sequences such as those profiled in tirzepatide ingredient breakdowns.

Red flags include certificates with no instrument traces, identical chromatograms reused across lots, missing retest dates, or purity figures reported without a stated method. Third-party testing from an independent laboratory carries more weight than in-house data alone. The broader vetting framework in how to tell if a peptide supplier is legitimate applies directly here, as does the general orientation in what research peptides are. Appearance checks — the kind outlined for expected colour in tirzepatide material — supplement but never replace documentation.

How should lyophilized Follistatin-344 be stored in a research laboratory?

Lyophilised Follistatin-344 is supplied as a sealed vial of dry protein, often with bulking excipients such as mannitol or trehalose. In that state it is comparatively stable, but storage conditions still govern how long the material retains structural integrity. Standard laboratory practice is freezer storage at −20 °C for shorter holding periods and −80 °C for long-term archiving, with vials kept desiccated, protected from light, and sealed against moisture ingress. Repeated removal from cold storage is the main avoidable stressor, because each warming cycle allows condensation on cold glass, and water is the principal driver of hydrolysis and aggregation in dried protein.

Once hydrated, a protein of this size is considerably less stable than its lyophilised form, and cold-chain handling becomes more important. Freeze–thaw cycling of solutions promotes aggregation that size-exclusion chromatography will later detect. Comparable cold-storage logic appears in laboratory notes on thymalin and on melatonin research handling. Compatibility also matters: guidance on what peptides should not be mixed with is relevant when planning buffers, and visual references such as cagrilintide solution appearance illustrate what clouding or particulates can indicate.

What is the regulatory status of Follistatin-344 for laboratory purchase?

Follistatin-344 is not an approved drug in the United States, the European Union, or other major jurisdictions. No marketing authorisation exists for any follistatin isoform, and it is supplied strictly as a research chemical for in vitro and preclinical investigation, labelled not for human consumption. That status means it is not manufactured under pharmaceutical GMP unless a supplier specifically documents otherwise, and no regulatory body has reviewed its safety or efficacy for any use in people.

Because it is a recombinant protein rather than a small molecule, Follistatin-344 may also fall under biologics-oriented rules in some jurisdictions, and import documentation can be scrutinised more closely than it is for short synthetic sequences. Anti-doping bodies list myostatin-pathway inhibitors as prohibited substances, which is a separate regulatory track from drug approval but relevant to institutional policy. Laboratories should review current frameworks — the overview in research peptide legality and FDA rules for 2026 covers how these categories are drawn — alongside background material on what research peptides are and compliance expectations described in supplier legitimacy checks. Similar status questions attach to compounds in the metabolic research peptide category.

How does Follistatin-344 compare with other muscle and recovery research compounds?

The comparison is largely one of mechanism class. Follistatin-344 is a ligand trap: it binds TGF-β superfamily members, including myostatin and activins, preventing receptor engagement. That is a sequestration mechanism acting upstream of a specific signalling cascade. Most other compounds studied in musculoskeletal contexts work differently. Agents discussed in the healing and recovery peptide mechanisms overview tend to act on angiogenesis, cytoskeletal dynamics, or growth-factor expression rather than on a single ligand-receptor pair, as the pairing described in BPC-157 and TB-500 mechanisms illustrates.

A further distinction separates Follistatin-344 from the growth hormone secretagogue class. Secretagogues act on GHS-R1a or GHRH receptors to modulate endogenous hormone release, producing systemic endocrine effects; the combinations examined under CJC-1295 and ipamorelin research sit squarely in that category. Follistatin-344 instead removes an inhibitory brake without stimulating a hormonal axis. It is also far larger — a folded multi-domain protein versus short synthetic chains — which affects stability, analytical requirements, and reported clearance behaviour in animal work, where circulating follistatin is cleared rapidly.

How does Follistatin-344 differ from follistatin gene therapy constructs?

Much of the published follistatin literature in muscle biology involves viral vector delivery rather than recombinant protein. In those studies, an adeno-associated virus carries a follistatin coding sequence into tissue, where transduced cells express the protein continuously for extended periods. The experimental question being asked is quite different from one using purified protein: gene delivery produces sustained local expression, while recombinant protein gives a transient exposure governed by clearance kinetics, which for follistatin isoforms is generally rapid.

This distinction matters when interpreting literature. Findings from vector-based studies cannot be transferred to protein-based experimental designs, because the exposure profile, tissue distribution, and duration differ fundamentally. Constructs used in gene therapy work are also frequently engineered variants rather than the native 344-residue sequence, sometimes modified to limit heparin binding or alter tissue retention. Laboratories planning work with purified material should treat vector studies as mechanistic context, not as a predictive model.

Similar interpretive care applies across the research peptide field, including compounds studied for longevity endpoints, in the metabolic research category, and in receptor-specific work such as that described for ARA-290, where delivery format shapes every reported outcome.

What should a laboratory check before sourcing Follistatin-344?

Sourcing a recombinant protein requires more scrutiny than sourcing a short synthetic sequence. Begin with the expression system: mammalian, insect, and bacterial hosts produce materially different products in terms of glycosylation and folding, and a supplier unable to state the host is unlikely to have meaningful manufacturing control. Request lot-specific analytical data rather than a generic product sheet, and confirm that HPLC traces, mass spectrometry results, and endotoxin figures correspond to the lot number on the vial.

Beyond analytics, assess operational signals: consistent lot numbering, stated retest dates, cold-chain shipping with temperature monitoring, and willingness to provide third-party test results. Clear research-use-only labelling is a positive indicator, not a limitation, because suppliers making therapeutic claims are operating outside the regulatory framework described in the 2026 FDA rules explainer. The structured evaluation in how to tell if a peptide supplier is legitimate translates directly to protein products.

Finally, orient new personnel with general background on what research peptides are and with handling documentation written for other compounds, such as research practices for Adamax, so that laboratory expectations around documentation are consistent across the inventory.